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Prevention and cure of infectious diseases remain a major challenge. Hepatitis C 
virus (HCV) infection is a leading cause of liver cirrhosis and cancer1. Tight 
junction (TJ) proteins mediate cell entry of HCV2,3 and other pathogens including 
dengue virus, coxsackievirus, adenovirus and shigella4-7. However, the role of TJ 
proteins as therapeutic targets is unknown. Using a human liver-chimeric mouse 5 
model8-10 we report that a monoclonal antibody specific for TJ protein claudin-111 
eliminates chronic HCV infection with undetectable toxicity. This antibody 
inhibits HCV entry, cell-cell transmission and virus-induced signaling events. 
Importantly, antibody treatment reduces the frequency of HCV-infected 
hepatocytes in vivo, highlighting the need for de-novo infection via host entry 10 
factors to maintain chronic infection. In summary, we demonstrate that an 
antibody targeting a virus receptor can cure chronic viral infection and uncover 
TJ proteins as targets for antiviral therapy, highlighting this novel host-targeting 
strategy for a broad range of pathogens. 
Word count: introductory paragraph 150 words, main text 2,817 words,  15 
methods 1,614 words 
  4 
The tight junction (TJ) proteins claudin-1 (CLDN1) and occludin have been shown to 
mediate hepatitis C virus (HCV) entry into host cells2,3. TJs have also been implicated in 
the entry of several other pathogens including dengue virus7, adenovirus4, 
coxsackievirus5 and shigella6. Although these reports demonstrate a role for TJ proteins 
in the life cycle of a broad range of pathogens, their role in viral pathogenesis and as 5 
targets for antiviral therapy are unknown. To address this question we used a recently 
developed CLDN1-specific monoclonal antibody (mAb)11 and the human chimeric uPA-
SCID mouse model8 to evaluate the therapeutic potential of this mAb to control acute 
and chronic HCV infection. Owing to discontinuation of research in chimpanzees for 
ethical reasons, this mouse model is the only available model that supports robust long-10 
term chronic HCV infection. Although these mice lack a functional immune system that 
precludes the study of immune-mediated events, this mouse model has contributed 
significantly to our understanding of viral pathogenesis, validation of antiviral strategies 
and the assessment of efficacy and safety profiles of antivirals9,10,12-17. 
 15 
 First, we analyzed CLDN1 expression in the chimeric liver using a commercially 
available mAb that recognizes human and mouse CLDN1 (Supplementary Fig.1). 
Confocal imaging demonstrated that the majority of CLDN1 on human hepatocytes co-
localized with apical marker CD10 demonstrating the formation of bile canalicular 
structures (Fig.1a). A minor pool of protein was detected at the basolateral membrane 20 
as identified with cytokeratin-8 staining (Fig.1a, data not shown and 18). Comparative 
staining of normal human liver tissue demonstrated comparable subcellular localization 
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(Fig.1a). Transmission electron microscopic (TEM) analysis confirmed that hepatocytes 
in the chimeric mouse liver form TJs that were structurally indistinguishable from those 
in human liver tissue (Supplementary Fig.2a-b). The similar localization of 
hepatocellular CLDN1 and hepatocyte architecture suggests that the uPA-chimeric 
mouse is a relevant model to evaluate CLDN1 as a therapeutic target. Next, we 5 
characterized the subcellular localization of CLDN1 recognized by the CLDN1-specific 
mAb (OM-7D3-B3) used in our mouse challenge studies. TEM and immunogold labeling 
of in vivo administered CLDN1-specific mAb showed reactivity with basolateral and 
sinusoidal hepatocyte membranes in vivo (Fig.1b), whereas we failed to detect staining 
of tight junctions (Fig.1b). Basolateral membrane staining was confirmed using live cell 10 
imaging of polarized HepG2 cells – a physiologically relevant cell line frequently used to 
study HCV entry (Fig.1c)19,20. Collectively, these data suggest that the CLDN1-specific 
mAb predominantly binds to non-junctional pools of CLDN1 on the hepatocyte 
basolateral membrane in vivo. 
 15 
 To investigate the antiviral effect of our CLDN1-specific mAb, chimeric uPA-SCID 
mice received CLDN1-specific (n=5) or control isotype matched irrelevant mAb (n=4) 
one day prior to inoculation, and 1 and 5 days post infection with a primary HCV 
genotype 1b serum. The CLDN1-specific mAb provided a complete and sustained 
protection from infection as evidenced by undetectable HCV RNA in the sera for up to 6 20 
weeks post-infection (Fig.2a, Supplementary Table 1). In contrast, all control mAb-
treated mice became infected (Fig.2a). Similar results were observed following infection 
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with a HCV of the difficult-to-treat genotype 4 (isolate ED4321, Fig.2b, Supplementary 
Table 1) demonstrating a significant level of anti-viral activity (p< 0.0002, pooled data 
from experiments of both genotypes, Mann-Whitney test). Pharmacokinetic studies 
showed that CLDN1-specific mAb levels declined rapidly and were undetectable 2 
weeks after administration (Fig.2f-g). Collectively, these data show that short-term 5 
administration of a CLDN1-specific mAb prevents de novo HCV infection and highlights 
a new opportunity to prevent HCV re-infection during liver transplantation. 
 
 To investigate the effect of the CLDN1-specific mAb on chronic HCV infection we 
utilized mice persistently infected with the cell culture-derived HCV (HCVcc) strain Jc1 10 
(genotype 2a/2a chimera)22, a prototype strain based on JFH123 that is used extensively 
to study virus-host interactions and to evaluate antivirals in vitro and in vivo22-26. 
Persistently infected mice (24 to 50 days post-infection) were given 4 weekly doses of 
CLDN1-specific (n=5) or control mAb (n=4). All CLDN1-specific mAb-treated mice 
showed undetectable HCV RNA levels after 2 to 4 injections (Fig.2c, Supplementary 15 
Table 1) and, except for one case, animals remained virus free until the end of the study 
period. The exception being one mouse that showed a relapse (Fig.2c, Supplementary 
Table 1), associating with low levels of antibody during the early treatment phase 
(Fig.2h). However, low levels of mAbs did not always correlate with relapse (Fig.2i-j). 
Sequencing and functional analysis of viral envelope glycoproteins from antibody-20 
treated mice in HCVpp and HCVcc (Supplementary Fig.3a-e) suggested that the 
relapse was unlikely to be explained by the presence of resistant variants that escaped 
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the CLDN1-specific mAb (Supplementary Fig.3c-d) or to CLDN1-independent cell entry 
(Supplementary Fig.3e). Of note, human hepatocytes engrafted into upA-SCID mice 
expressed lower levels of CLDN6 than Huh7.5.1 cells used for escape studies 
(Supplementary Fig.4a-d). These data suggest that the absent escape observed in the 
HCV-Huh7.5.1 cell culture model expressing high levels of CLDN6 is relevant for HCV 5 
infection in vivo. The mAb concentration peaked during the treatment period and 
declined rapidly following discontinuation of mAb injection (Fig.2h). Similar results were 
observed in 4 additional Jc1-infected CLDN1-specific mAb-treated mice with follow-up 
of 3 weeks (data not shown). CLDN1 mAb induced viral clearance from mice chronically 
infected with HCVcc VL-JFH1 (genotype 1b/2a chimera) (n=5), a well characterized 10 
strain27 encoding the structural proteins from a highly infectious HCV neutralization 
escape variant isolated from a patient undergoing liver transplantation12 (Fig.2d, 
Supplementary Table 1). One mouse showing a partial viral response (Fig.2d, 
Supplementary Table 1) was characterized by undetectable mAb concentration after the 
second injection (Fig.2i). The therapeutic effect was robust (HCV RNA decline > 2 logs), 15 
sustained (until the end of the study period corresponding to 11 weeks) and significant 
(p< 0.0007, pooled data for experiments of both genotypes, Mann-Whitney test). 
Furthermore, a similar effect was observed in mice chronically infected with a genotype 
2a serum confirming the antiviral activity using an inoculum with high viral diversity 
(Fig.2e, Supplementary Table 1). Mice infected with primary isolates of genotype 4 20 
(n=4) also showed a marked and time-dependent decrease in HCV RNA levels 
(Supplementary Fig.5a) with no viral rebound and stable function of the engrafted 
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human hepatocytes as shown by serum albumin levels (Supplementary Fig.5b). In 
summary, these data show that a CLDN1-specific mAb can clear chronic HCV infection 
in vivo and exhibits antiviral activity against different viral genotypes. These findings 
uncover a TJ protein as a therapeutic target in a clinically relevant animal model and 
highlight a previously unknown property of an inhibitor targeting a cell entry factor. 5 
 
 To assess antibody safety, we analyzed the histopathology of chimeric livers 
from uPA-SCID mice. Human hepatocyte-specific staining demonstrated similar 
repopulation and structure of human hepatocytes in HCV Jc1-infected mice treated with 
control or CLDN1-specific mAb (Supplementary Fig.6a). TEM analysis of chimeric 10 
infected livers of treated mice showed no detectable alteration in hepatocyte 
morphology or TJ ultra-structure (data not shown). Human albumin, transaminases 
(ALT, AST) and total bilirubin levels remained stable following antibody administration 
and were similar in control and CLDN1 mAb-treated mice at all time points tested 
(Supplementary Fig.6b-e). To assess the functional integrity of human hepatocytes in 15 
CLDN1 mAb-treated mice we challenged the mice with HCV of a different strain and 
genotype. Indeed, CLDN1 mAb-treated animals previously protected from HCV infection 
(Fig.2a) supported viral infection following elimination of the CLDN1-specific mAb 
(Supplementary Fig.6f). These functional data corroborate the presence of fully viable 
and functional hepatocytes following anti-CLDN1 treatment and exclude adverse effects 20 
on hepatocyte function in vivo. 
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 To address potential side effects of the CLDN1-specific mAb in other organs and 
tissues we assessed antibody binding to human and murine CLDN1 (Supplementary 
Fig.7a-g). The antibody bound primary mouse hepatocytes and 293T cells expressing 
murine CLDN1 with an apparent Kd of 83.6 ± 14.1 nM compared to the apparent Kd for 
human CLDN1 expressed in 293T cells (17.05 ± 1.14 nM) (Supplementary Fig.7g). 5 
Moreover, the latter was in a similar range as the Kd of CLDN1-specific mAb binding to 
human hepatocytes11. Next we measured in vivo biodistribution in Balb/c and observed 
enrichment in skin, kidneys, lungs, intestines and liver (Supplementary Fig.9a-b). 
Toxicity studies in Balb/c mice including clinical (data not shown), biochemical and 
hematological parameters such as blood counts, liver and kidney function tests as well 10 
as histopathological analyses did not reveal toxicity in any of the analyzed organs 
(Supplementary Fig.8, Supplementary Tables 2, 3). Since TJs play a key role in 
intestinal paracellular permeability, we investigated the effect of our CLDN1-specific 
mAb on intestinal barrier function in vivo. The CLDN1-specific mAb had no effect on 
intestinal paracellular permeability (Supplementary Fig.9c) or total intestinal transit time 15 
(Supplementary Fig.9d), in contrast to irradiated mice that were used as positive control. 
Additional ex vivo studies showed that the CLDN1-specific antibody had no detectable 
effects on paracellular permeability (Supplementary Fig.9e) or tissue conductance in the 
small intestine or colon (Supplementary Fig.9f). Intestinal epithelial barrier function upon 
CLDN1-specific mAb administration was further confirmed in vitro by demonstrating that 20 
the mAb had no effect on the gut intestinal Caco-2 trans-epithelial electrical resistance 
(Supplementary Fig.9g) that are known to express abundant levels of CLDN1 
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(Supplementary Fig.9h). We confirmed that the antibody had no effect on TJ function in 
the hepatic HepG2 model system28. While CLDN1 knock-down significantly reduced TJ 
integrity in a model of polarized HepG2 cells (Supplementary Fig.10a-b), the CLDN1-
specific mAb had no impact (Supplementary Fig.10c). Furthermore, flow cytometry 
experiments measuring CLDN1 cell surface expression suggested that the CLDN1-5 
specific mAb did not promote cellular CLDN1 internalization (Supplementary Fig.10d). 
Finally, a detailed analysis of cytokine mRNA expression in antibody-treated mice did 
not reveal evidence for antibody-induced inflammatory changes in the mouse jejunum 
(data not shown). Collectively, these data exclude major toxicity or side effects induced 
by the CLDN1-specific mAb in mice. Due to the absent interaction of the rat antibody 10 
with the mouse Fc receptor, immune-mediated adverse effects, e.g. ADCC, cannot be 
assessed in this model. Humanization of the antibody using an IgG4 backbone – a well 
established strategy to minimize ADCC29,30 – is underway for its clinical development. 
 
 To explore the antiviral mechanism of the CLDN1-specific mAb, we performed 15 
both in vitro and in vivo studies. Using protein association studies and a Förster 
resonance energy transfer (FRET)-based assay, we found that the CLDN1-specific mAb 
interfered with CD81-CLDN1 co-receptor complex formation (Supplementary Fig.11a) - 
a key step required for HCV entry19. Co-receptor perturbation most likely occurs at the 
hepatocyte basolateral membrane as shown by immunofluorescence studies of 20 
polarized HepG2 cells or immunogold affinity labeling of hepatocytes (Fig.1b-c). 
Furthermore, we demonstrate that the CLDN1-specific mAb significantly inhibits cell-
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free and cell-cell routes of transmission31 (Supplementary Fig.11b-e). Of note, inhibition 
of cell-cell transmission led to a marked decrease of virus spread in the hepatoma cell 
culture model when the CLDN1-specific mAb was added 48h post-infection 
(Supplementary Fig.11e). The ability of the antibody to inhibit cell-free and cell-cell 
infection may explain, at least in part, the antiviral effects of the CLDN1-specific mAb to 5 
cure persistent HCV infection in vivo. Since this mAb neither impaired HCV replication 
nor assembly/release (Supplementary Fig.11f-g), we conclude that the mAb acts 
predominantly by interfering with HCV entry. 
 
Since CLDNs have been shown to play a role in modulating miRNA expression 10 
and signaling pathways32,33, we investigated whether the antibody modulated the 
miRNA and kinome profile of persistent HCV-infected Huh7.5.1 cells. Consistent with 
previous observations34 our deep sequencing studies confirmed that HCV infection 
modulates miRNA profiles in Huh7.5.1 cells. However, the CLDN1-specific mAb had no 
detectable effect on miRNA expression (Supplementary Fig.12). 15 
 HCV binding to hepatocellular CD81 and associated receptors activates EGFR 
and mitogen-activated protein kinase (MAPK) pathway signaling35,36. HCV (Jc1) 
infection increased Erk1/2 phosphorylation and this was reversed by the CLDN1-
specific mAb (Fig.3a-b). The significance of HCV-induced MAPK signaling was 
supported by analyzing liver biopsies from HCV infected patients (Fig.3c-d, 20 
Supplementary Table 4, p< 0.05, Mann-Whitney test). Importantly, we observed an 
antiviral effect of small molecule inhibitors targeting MAPK signaling (Fig.3e) at non 
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toxic concentrations10,37 (Supplementary Table 5). To confirm the effect of the CLDN1-
specific mAb on HCV-induced signaling in liver tissue from HCV-infected patients 
(Supplementary Table 4), freshly isolated liver biopsies were treated ex vivo with 
CLDN1-specific or control mAb and we observed a reduction of Erk1/2 phosphorylation 
compared to control-treated biopsies (Fig.3f). These studies show that HCV infection 5 
activates MAPK signaling and CLDN1-specific mAb partially reverses this virus-
dependant signaling event without impairing Erk activation by the physiological EGFR 
ligand EGF (Fig.3g-h). Collectively these data suggest a model in which the anti-CLDN1 
mAb prevents the HCV-induced cross-activation of EGFR and Erk by interfering with 
CD81-CLDN1 association (Fig.3i). Since MAPK signaling pathway has been shown to 10 
play an essential role in the HCV life cycle, including viral entry37,38, it is likely that this 
interference contributes to the ability of the mAb to clear an established infection.  
 
 Finally, we performed mechanistic studies in human chimeric mice to study the 
consequences of the observed mechanistic findings for viral clearance in vivo. Using 15 
FISH with HCV- and human GAPDH-RNA specific probes (Fig.4a) we demonstrate that 
CLDN1-mAb results in a dose- and time-dependent decrease in the number of HCV-
infected cells leading to their final elimination (Fig.4b). Furthermore, the decline of HCV-
infected hepatocytes paralleled the decline in peripheral HCV RNA levels, showing a 
monophasic decline (Fig.4b, Supplementary Fig.13). Of note, the baseline frequency of 20 
HCV-infected hepatocytes (Fig. 4b) in the chimeric mouse liver were comparable to 
those reported in the chronically infected human liver39.  
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 Assuming an inhibition of entry of > 99% at mAb serum concentrations exceeding 
100 ug/mL (as shown in Supplementary Fig.11) and a negligible effect on viral genome 
replication and/or assembly (Supplementary Fig.11f-g), mathematic modeling predicts a 
time-dependent elimination of virus-infected hepatocytes with concomitant absent de-
novo-infection. Applying this model, we estimated the half-life of infected cells to be ~ 5 
1.3 days for genotype 2a and 5.4 days for genotype 4 which is in the range of 
hepatocytes half-lives reported in patients40. Indeed, HCV has been reported to promote 
cellular apoptosis in vitro and in vivo (Supplementary Fig.14 and 41,42). During serum 
HCV RNA decline, virus infected hepatocytes are constantly replaced by non-infected 
hepatocytes, as shown by very stable human albumin levels (Supplementary Figs.5b, 10 
6b), resulting in viral control and clearance. This model is supported by both FISH 
analyses of liver tissue sections (Fig.4) and in vitro studies where CLDN1-specific mAb 
eliminates HCV-infected cells (Supplementary Fig.14c-d). The different half-lives of 
HCV-infected cells and the magnitude of virus-induced cell death may explain the 
varying magnitude of the decline in viral load for diverse HCV strains (Supplementary 15 
Figs.5a, 13)40. 
 
 In contrast to previous studies reporting on CD81- and SR-BI-specific antibodies 
preventing virus infection of human chimeric mice9,14, we demonstrate for the first time 
that a host-targeting entry inhibitor clears chronic viral infection (Fig.2c-e). Our results 20 
show that viral entry and spread are required for persistent infection in vivo and that TJ 
protein CLDN1 is a valid target to both prevent and treat chronic HCV infection. The 
  14
interaction of the mAb with non-junctional pools of CLDN1 (Fig.1b-c) that complex with 
the viral co-receptor CD81 (Supplementary Fig.11a), may explain the non-detectable 
toxicity (Supplementary Figs.6a-f, 8, 9c-g, Supplementary Tables 2, 3). This is in line 
with our results showing a specific role for the CLDN1-specific mAb to perturb MAPK 
signaling events in infected cells and liver tissue but to have no effect on naïve target 5 
cells (Fig.3a-b, f). 
 
 In summary, therapeutic administration of a CLDN1-specific mAb demonstrates 
broad and marked activity against several genotypes (Fig.2, Supplementary Fig.5, 11b) 
without detectable toxicity as determined by structural, biochemical and functional 10 
assays (Supplementary Figs.6, 8, 9, Supplementary Tables 2, 3). The absence of 
detectable viral resistance (Supplementary Fig.3) suggests that CLDN1 is an antiviral 
target with a high genetic barrier for resistance. Although a recent report described 
strain-dependent use of CLDN1 and 6 in hepatoma cell lines in vitro43, our in vivo data 
suggest that the antiviral effect of the CLDN1-specific mAb is independent of viral strain, 15 
genotype and hepatocyte donors (Fig.2, Supplementary Figs.5a, 11b). Collectively, 
these data suggest that CLDN1 is essential for HCV infection in vivo and that low 
expression levels of CLDN6 and CLDN9 in human hepatocytes (Supplementary Fig.4 
and 43,44) preclude a relevant entry function of these molecules in vivo.     
 20 
 In contrast to direct-acting antivirals in clinical use or development, the CLDN1-
specific mAb eliminates viral infection in monotherapy in the current state-of-the-art 
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animal model (Fig.2, Supplementary Fig.5a) and does not result in detectable 
resistance (Supplementary Fig.3). We predict that these features are due to its unique 
mechanism of action targeting a host cell factor (Supplementary Fig.11a) that is 
essential for viral persistence in vivo as well as modulating host cell signaling of virus-
infected cells (Fig.3) likely contributing to clearance. Collectively, these data suggest 5 
that antibodies or small molecules targeting CLDN1 are promising candidates to prevent 
liver graft infection and to eliminate chronic HCV infection. Finally, our proof-of-concept 
study uncovering CLDN1 as target for cure of HCV infection allows the design of novel 
antimicrobial strategies for a broad range of viruses and pathogens that utilize TJ 
proteins as host factors including dengue virus, coxackievirus, adenovirus and shigella 10 
4-7. 
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FIGURE LEGENDS 
Figure 1. Human CLDN1 expression and tight junction ultrastructure in the livers 
of human chimeric mice. (a) Human CLDN1 expression in non-infected chimeric livers 
of uPA-SCID mice (left panel) as well as non-infected human livers (right panel) was 
assessed by confocal microscopy as described in Methods. Representative 3D 5 
composite images show human CLDN1 (green) co-stained with apical membrane 
marker human CD10 (red). Scale bars – 20 μm. (b) Binding of CLDN1-specific mAb to 
hepatocyte ultrastructures was assessed by transmission electron microscopy analyses 
and immunogold labeling of tissue sections of chimeric human mouse livers from mAb-
treated mice. Images show TJ area (left panels) or basolateral membranes of 10 
hepatocytes (right panels). Red arrows indicate TJ, empty triangles indicate 
immunogold staining. Scale bars – 500nm. (c) Confocal microscopy of polarized 
HepG2-CD81 HCV permissive cells stained with CLDN1-specific antibody. HepG2 
DsRED-CD81 cells were stained live with CD81- (upper panels) or CLDN1-specific 
(lower panels) antibodies and visualized by confocal microscopy. CLDN-1 specific 15 
staining is predominantly limited to the basolateral membrane of polarized cells. Scale 
bar – 20μm. 
 
Figure 2. Prevention and clearance of chronic HCV infection using a CLDN1-
specific mAb in vivo. (a, b) Prevention studies. Chimeric uPA-SCID mice received 500 20 
μg CLDN1-specific (n=5) or control mAb (n=4) on days -1, 1 and 5 (arrows) of 
inoculation (star) with genotype 1b (a) or genotype 4 (b) HCV-containing serum. One 
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infected mouse injected with control mAb died on day 26 (a, cross). (c-e) Treatment 
studies. Chimeric uPA-SCID mice were chronically infected with HCVcc Jc122 (genotype 
2a/2a) (c), HCVcc VL-JFH127 (genotype 1b/2a) (d) or serum of genotype 2a (e). 
Twenty-four to 50 days following inoculation, the animals received 500 μg control (c, d, 
e; n=4, 3 and 4 respectively) or CLDN1-specific mAb (c, d, e; n=5, 5 and 6 respectively) 5 
each week (arrows) for 4 weeks. (f-j) Serum concentration of CLDN1-specific mAb from 
(a-e respectively) was determined by ELISA. Serum viral load (a-e) was quantified by 
the clinically licensed Abbott RealTime™ HCV assay. The horizontal dashed line 
indicates the limit of quantification (LOQ). (c, d, h, i) The viral load and antibody 
concentration of the mice exhibiting a relapse is indicated by a dotted line. Values of 10 
individual animals are shown. 
 
Figure 3. CLDN1-specific mAb impairs HCV-induced host cell signaling. (a) 
Detection of kinase phosphorylation in chronically HCV Jc1-infected Huh7.5.1 cells 
treated with control or CLDN1-specific mAbs (100 μg/mL; 24h) using human phospho-15 
kinase arrays. (b) p-Erk1/2 highlighted by black squares in (a) was quantified using 
Image J software (NIH). Results are shown as mean ± s.e.m. of integrated dot blot 
densities from 2 independent experiments performed in duplicate. (c) Erk1/2 
phosphorylation is elevated in liver tissue of patients with chronic HCV infection. 
Expression of p-Erk, total Erk and actin was revealed by Western blotting. (d) 20 
Quantification of signal intensities of p-Erk1/2 in (c) normalized to total Erk expression. 
Results are shown as the interquartiles (box) with the min and max values (whiskers). 
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The line within the box indicates the median value. (e) Inhibition of the MAPK pathway 
inhibits persistent HCV infection in Huh7.5.1 cells. Luc-Jc1-infected Huh7.5.1 cells were 
treated 3 days after inoculation with erlotinib or UO126 (each at 10 μM) for 3 days. HCV 
replication was assessed by luciferase assay. Results are presented as mean ± s.e.m 
of 6 independent experiments performed in triplicate. (f) CLDN1-specific mAb reduces 5 
Erk1/2 phosphorylation in liver tissue from patients with chronic HCV infection. Fresh 
liver biopsies were divided in two equal pieces and maintained in DMEM medium 
supplemented with 10% foetal calf serum and 100 μg/mL control or CLDN1-specific 
mAb for 4h, respectively. Expression of p-Erk, total Erk and actin was determined by 
Western blotting. Information on liver biopsies is provided in Supplementary Table 4. (g) 10 
CLDN1-specific mAb does not inhibit EGF-induced Erk1/2 phosphorylation. Huh7.5.1 
cells were serum starved for 4h prior 1h incubation with 100 μg/mL control or CLDN1-
specific mAb and 15 min incubation with increasing concentrations of EGF. P-EGFR, p-
Erk1/2 and total Erk were quantified by Western blotting. (h) Quantification of EGF-
induced ERK phosphorylation in the presence of CLDN1-specific or control mAb. P-Erk 15 
and total Erk Western blot signals described in (g) were quantified using a Typhoon Trio 
laser scanner and ImageQuant Software (GE Healthcare). Values are expressed as 
relative ratio of p-Erk to total Erk densities (two independent experiments ± s.e.m.). (i) 
Model of HCV-induced signal transduction during cell entry (left panel) and its 
impairment by CLDN1-specific mAb (right panel). (Left panel) (I) HCV entry is 20 
dependent on EGFR signaling which promotes CD81-CLDN1 co-receptor interactions 
according to Zona et al.37 and Lupberger et al.10 (II) At the same time viral binding to the 
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target cell induces EGFR phosphorylation and signaling via CD81-EGFR interactions as 
shown by Diao et al.36 and (III) MAPK signaling according to Brazzoli et al. by cross-
talk35. (Right panel) Combining these observations and results shown in panels (a-h) 
and Supplementary Fig.10, our findings are consistent with a model that the CLDN1-
specific mAb impairs virus-induced MAPK/Erk signaling by interfering with 5 
CD81/CLDN1-MAPK cross-talk without impairing direct EGF-induced Erk 
phosphorylation. *p<0.05, **p<0.01, ***p<0.0001 (Student’s t-test (b, e), Mann-Whitney 
test (d)). 
 
Figure 4. CLDN1-specific mAb leads to elimination of HCV-infected cells from the 10 
livers of human chimeric mice in a dose and time-dependant manner. (a) Detection 
of human hepatocytes and HCV RNA with probes specific for human GAPDH mRNA 
(green) or HCV Jc1 RNA (red) using FISH. The specificity of the HCV- and GAPDH 
probes are shown by specific staining of HCV-infected human hepatocytes and absent 
staining of uninfected human liver (left top panel) and Balb/c mouse liver (right top 15 
panel). FISH analyses were then performed in livers of control (left bottom panel) or 
CLDN1-specific mAb (right bottom panel) treated chimeric uPA-SCID mice. Red arrows 
indicate HCV positive cells. Scale bar – 50μm. (b) Quantification of the percentage of 
infected cells in the liver of uninfected chimeric mice (black circles) or HCV Jc1-infected 
mice treated either four times with control mAb (grey triangles), or once (blue diamonds) 20 
or four times (blue circles) with CLDN1-specific mAb. Livers were collected 1 week after 
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the last antibody injection. The quantification was performed after confocal microscopy 
acquisition. 
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METHODS 
Antibodies. The human CLDN1-specific (OM-7D3-B3, IgG2b, rat11), CLDN6-specific 
(WU-9E1-G2, IgG2b, rat44), CLDN9-specific (YD-4E9-A2, IgG2b, rat44) mAbs, HCV E2-
specific AP33 (mouse)11, E1-specific IGH433 (human)11 mAbs and patient-derived 
HCV-specific IgG11 have been described. Control mAb (rat IgG2b clone LTF-2, Bio X 5 
Cell), Human CLDN1-specific (Life Technologies, rabbit; R&D, rat polyclonal), human 
CD10-specific (clone 56C6, Vector Laboratories, mouse), human CD81-specific (clone 
2s131, mouse), human CK18-specific (clone VP-C414, Vector Laboratories, mouse), 
Alexa-fluor 488 conjugated IgG rabbit-specific, Alexa-fluor 488 conjugated IgG mouse-
specifc, Alexa-fluor 488 conjugated IgG rat-specific and Alexa-fluor 594 conjugated IgG 10 
mouse-specific Abs (Invitrogen, goat) were used for fluorescent imaging as described45. 
Erk1/2 (rabbit), pErk1/2 (Thr202, Tyr204, mouse, clone E10, Cell Signaling)-specific 
antibodies and alkaline–phosphatase (AP)–labeled secondary antibodies (GE 
Healthcare) were used for immunoblot analyses. Rabbit anti-rat bridging antibody 
(Cappel #55704) was used for immunogold labeling. 15 
 
Cell lines. Huh7.5.1, Huh7.5-GFP, Huh7.5 shCD81.1, 293T, HepG2 DsRed-CD81 and 
Caco-2 cells were cultured as described10,46-49. 
 
Imaging of CLDN1 in human and chimeric livers. Chimeric mouse and human liver 20 
samples were formalin fixed and paraffin embedded. Human liver tissue was obtained 
from patients undergoing liver transplantation due to HCV or from normal livers taken 
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from surplus donor tissue used for reduced size transplantation. Informed consent from 
each patient was obtained with regional ethics committee approval (project number 
04/Q2708/40). Sections were subjected to low temperature antigen retrieval pre-
treatment, followed by fluorescent detection of CLDN1, CD10 or CK18 as previously 
described45. Labeled sections were visualized using laser scanning confocal microscopy 5 
(Zeiss LSM 780, 100 x Plan Apochromat 1.4NA oil immersion objective). Background 
and autofluorescence of tissue samples were corrected throughout and 3D composite 
images were generated using the Zeiss Zen analysis software. 
 
Transmission electron microscopy and immunogold labeling of CLDN1 in vivo. 10 
Human liver-chimeric mice were injected with 500 μg control or CLDN1-specific mAb 
and sacrificed 5h later. Mice were perfused with PBS for 3 min through portal vein 
infusion followed by 5 min perfusion with 4% electron microscopy (EM)-grade 
paraformaldehyde (PFA). Livers were harvested, minced in 3 mm pieces and fixed in 
4% PFA at room temperature for 24h. Subsequently liver pieces were placed in PBS 15 
and kept at 4°C before processing for EM. Prior to freezing in liquid nitrogen the tissue 
were infiltrated with 2.3M sucrose in PBS containing 0.2M glycin for 15 min. Frozen 
samples were sectioned at -120°C, the sections were transferred to formvar-carbon 
coated copper grids. Grids were floated on PBS at room temperature (RT) until the 
immunogold labeling was carried out at RT on a piece of parafilm using CLDN1-specific 20 
mAb, rabbit anti-rat bridging antibody and 15nm Protein-A gold. Contrasting/embedding 
of the labeled grids was carried out on ice in 0.3% uranyl acetete in 2% methyl cellulose 
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for 10 min. Grids were examined in a JEOL 1200EX Transmission electron microscope 
and images were recorded with an AMT 2k CCD camera. 
 
CLDN1 staining on polarized HepG2 cells. HepG2 DsRED-CD81 cells were grown on 
13 mm diameter borosilicate glass coverslips at 4x104 cells/coverslip (Fisher Scientific, 5 
UK). Laser scanning confocal microscopy (LSCM) was performed on a Zeiss Meta 
Head Confocal Microscope with a 63x water immersion objective. For live cell receptor 
staining of CD81 and CLDN1 in HepG2 DsRED-CD81 cells, cells were washed twice 
with PBS before blocking in PBS-BSA-0.01% sodium azide (Sigma, UK) for 15 min. 
Cells were incubated with the following primary antibodies: anti-CD81 (1μg/mL) and 10 
anti-CLDN1 (1:200) in PBS-BSA-azide for 30 min at 37oC. Cells were washed 3x in PBS 
before fixing with 3.6% PFA for 30 min. Cells were washed 3x with PBS before addition 
of a goat anti-mouse secondary Ab (Alexa 488, Invitrogen) at a 1:1000 dilution in PBS-
BSA-azide or a goat anti-rat secondary Ab (Alexa 488, Invitrogen) for 30 min at 37oC. 
Cells were then washed with PBS before mounting and visualization. 15 
 
Human liver-chimeric mice. Human liver-chimeric mice were produced by 
transplanting cryopreserved human hepatocytes into the spleen of 3 week-old 
homozygous urokinase-type plasminogen activator-transgenic Severe Combined 
Immuno-Deficiency-beige of both sex (uPA-SCID-bg) mice8,15.  20 
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In vivo experimentation. For prevention studies, chimeric uPA-SCID mice were 
intraperitoneally injected with 500 μg CLDN1-specific or control mAb at day -1 before 
and days 1 and 5 after inoculation of a genotype 1b or 4 HCV-infected serum. HCV 
infection was performed as previously described8. For treatment studies, chimeric uPA-
SCID mice were chronically infected with HCVcc of prototype strain Jc122, a genotype 5 
1b/2a chimeric VL-JFH127 or genotype 2a and 4 serum. Chronically infected mice 
received 500 μg CLDN1-specific or control mAb once a week for 4 weeks, except for 
genotype 4 where mice received 2 injections per week throughout the study period. 
Blood was harvested by retro-orbital puncture under general anesthesia. Experiments 
were performed in the Inserm Unit 1110 animal facility according to local laws and 10 
ethical committee approval (AL/02/19/08/12 and AL/01/18/08/12).  
 
Viral load. Viral load was quantified using Abbott RealTime™ HCV assay (Abbott). The 
linear range of the assay is 12 IU/mL to 108 IU/mL, the limit of quantification (LOQ) of 
HCV RNA is 12 IU/mL. Given a mouse serum dilution of 1:100 in PBS, LOQ is 1200 15 
UI/mL, i.e. 5160 copies/mL.  
 
Analysis of CLDN1-specific mAb serum concentrations. Serum antibody 
concentrations were quantified using a rat IgG2b antibody-specific ELISA (ref. E110-
111, Bethyl Laboratories, Euromedex) following the recommendations of the supplier. 20 
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Liver biopsies. Eligible patients were identified by a systematic review of patient charts 
at the Hepatology outpatient clinic of the University Hospital of Basel, Switzerland. The 
protocol was approved by the Ethics Committee of the University Hospital of Basel, 
Switzerland. Written informed consent was obtained from all patients. Histopathological 
grading and staging of the HCV liver biopsies according to the Metavir classification 5 
system was performed at the Pathology Institute of the University Hospital Basel and 
are summarized in Supplementary Table 3. All patients that donated liver tissue were 
male between 27 and 61 years old and female between 39 and 62 years old 
(Supplementary Table 4). Liver biopsy tissues from patients were analyzed as 
described50. In brief, liver tissue was lysed in 100 mM NaCl, 50 mM Tris pH 7.5, 1 mM 10 
EDTA, 0.1 % Triton X-100, 10 mM NaF, 1 mM PMSF, and 1 mM sodium ortho-vanadate 
during mechanic homogenization followed by 20 min incubation on ice. Lysates were 
cleared by centrifugation at 4 °C and 21,000 x g for 5 min prior to immunoblot analysis 
of 5 μg protein per sample. For ex vivo stimulation, fresh liver biopsies were divided in 
two equal pieces and incubated for 4h at 37°C in DMEM medium supplemented with 15 
10 % fetal calf serum and 100 μg/mL control or CLDN1-specific mAb, respectively. 
 
Analysis of protein expression and phosphorylation. Immunoblots of cell lysates 
using Erk1/2-specific antibodies were performed using Hybond–P membranes and 
visualized using ECF substrate (GE Healthcare) according to the manufacturer’s 20 
protocol. Fluorescence emission was detected using Typhoon Trio high performance 
fluorescence scanner (GE Healthcare) and quantified using Image Quant TL software 
  33
(GE Healthcare). Phospho-array analysis was performed using Proteome Profiler 
Human Phospho-kinase Array (R&D Systems) as described by the manufacturer. For 
imaging, blots were incubated with ECL (GE Healthcare) and exposed to ECL Hyperfilm 
(GE Healthcare). Phospho-kinase array results were quantified by integrating the dot 
blot densities using Image J software (NIH). 5 
 
Inhibition of HCV infection by protein kinase inhibitors. Huh7.5.1. cells were plated 
in 96 well-plates (2 x 103 cells/well) and infected 24h later for 3 days with HCVcc Luc-
Jc1. Medium was then removed and replaced with medium containing 10 μM erlotinib 
(LC Laboratories) or UO126 (Calbiochem) and final concentration of 1% DMSO. Control 10 
medium contains only 1% DMSO. Three days later, HCV replication was quantified by 
luciferase activity measurement. 
 
EGF-induced MAPK activation. Huh7.5.1 cells were serum starved for 4h prior 1h 
incubation with 100 μg/mL control or CLDN1-specific mAb and 15 min incubation with 15 
increasing concentrations (1, 10 and 100 ng/mL) of EGF. P-EGFR, p-Erk1/2 and total 
Erk were detected by Western blotting. Quantification was performed using a Typhoon 
Trio laser scanner and ImageQuant Software (GE Healthcare). 
 
FISH analyzes of human chimeric livers. Liver samples from mice were collected 20 
during necropsy, immediately embedded in optimal cutting temperature compound 
(OCT) and frozen in liquid nitrogen chilled 2-methylbutane. Tissues were then stored at 
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-80°C until use. Sections (10 μm) were cut at cryostat (Leica), fixed overnight in 4% 
formaldehyde at 4°C and hybridized, as previously described39, with the following 
modifications. Briefly, tissue sections were pre-treated by boiling (90°-95°C) in pre-
treatment solution (Affymetrix – Panomics) for 1 min, followed by a protease QF 
(Affymetrix – Panomics) digestion for 10 min at 40°C. Hybridization was performed 5 
using probe sets against JFH-1 HCV RNA (target region 4513-6253) and against 
human GAPDH mRNA (VA6-12786-06, Affymetrix-Panomics). Pre-amplification, 
amplification and detection were performed according to provider’s protocol. Images 
were acquired with a LSCM (LSM710, Carl Zeiss Microscopy, Göttingen, Germany) and 
Zen2 software, using same settings for all the tissues analyzed. Five to seven random 10 
fields were selected from each section, based only on the presence of human GAPDH 
signal to ensure the presence of human hepatocytes. Images were then acquired also 
including the channel for the HCV detection. Image analysis was performed using 
ImageJ and CellProfiler software, with a customized pipeline. Total number of cells, 
number of human hepatocytes (HH), number of HCV+ HH and HCV signal average 15 
intensity (and s.d) were evaluated. 
 
Statistical analyzes. For in vivo and ex vivo data, the one-way ANOVA followed by 
Tukey’s Post-Hoc test or the Kruskall-Wallis followed by Dunn’s Post Hoc test were 
used after determination of distribution by the Shapiro-Wilk normality test. The Wilcoxon 20 
rank test as well as the two-tailed Mann-Whitney test were also used. The in vitro data 
are presented as the mean ± s.d. except where mean ± s.e.m. is indicated, and were 
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analyzed by the unpaired Student’s t-test or the two-tailed Mann-Whitney test as 
indicated. A p-value ≤ 0.05 was considered significant. Statistical analyzes were 
performed with GraphPad Prism 6 software. 
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